Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Director | June 10, 2026 | June 11, 2026 |
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Director | January 07, 2026 | January 09, 2026 |
| Precipio, Inc.PRPO · Entity 7207 | Director | January 15, 2026 | January 20, 2026 |
| Q32 Bio Inc.QTTB · Entity 5594 | Director | June 12, 2026 | July 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Biotherapeutics, Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2036-06-09 | Direct | 5,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 5,000 · Balance 5,000 F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
CERO THERAPEUTICS HOLDINGS, INC.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2036-01-06 | Direct | 690,900 |
Reported balance
After 2026-01-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 690,900 · Balance 690,900 |
Precipio, Inc.
Report date January 15, 2026 · Filed January 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,382 |
Reported balance
After 2026-01-15 transaction · row 1
1 source rowRow 1 · 2026-01-15 · Grant · Acquired 520 · Balance 7,382 F1: 520 shares of common stock were granted upon the close of business on January 15, 2026, as consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q4-25. |
Filing footnotes · ownership attribution and instrument terms
F1: 520 shares of common stock were granted upon the close of business on January 15, 2026, as consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q4-25.
Q32 Bio Inc.
Report date June 12, 2026 · Filed July 22, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2036-06-11 | Direct | 10,826 |
Reported balance
After 2026-06-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 10,826 · Balance 10,826 F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
89bio, Inc.
Report date October 30, 2025 · Filed October 31, 2025
Section 16 reporting ended · disclosed 2025-10-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.68 · Expires 2031-11-01 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2032-05-16 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-30 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.70 · Expires 2033-02-09 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-30 · Disposition to issuer · Disposed 27,400 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.98 · Expires 2034-02-01 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-30 · Disposition to issuer · Disposed 45,150 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.60 · Expires 2035-02-01 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-30 · Disposition to issuer · Disposed 56,400 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]
F2: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F3: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4]
F4: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]
F5: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 16, 2026 20:30 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-272701 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 12, 2026 Filed Jul 22, 2026 00:39 UTC Amendment | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 10,826 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-310980 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 20:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001193125-26-267558 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:16 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 520 | $24.00 | $12,480.00 |
DisclosureSEC source: 0001104659-26-005043 · tm263642-2_4seq1.xml · nonDerivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,382 F1 · shares: 520 shares of common stock were granted upon the close of business on January 15, 2026, as consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q4-25. F1 · price: 520 shares of common stock were granted upon the close of business on January 15, 2026, as consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q4-25. Read SEC document |
| January 15, 2026 Filed Jan 31, 2026 00:00 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 23,272 | $2.75 Strike: $3.60 | $63,998.00 |
DisclosureSEC source: 0001193125-26-032248 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,272 Underlying: Common Stock · 23,272 shares Expires 2036-01-14 F1 · price: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported. F1 · derivative.exercise_date: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Stock Option and Incentive Plan and pursuant to the Issuer's non-employee director compensation policy. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued service through such date and represents the Reporting Person's election to receive stock options in lieu of cash retainer fees. Due to administrative oversight this option award initially was not reported. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:30 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 690,900 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001213900-26-002947 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 690,900 Underlying: Common Stock · 690,900 shares Expires 2036-01-06 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:33 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $23.82 | $0.00 |
DisclosureSEC source: 0001104659-26-001350 · tm261953-6_4seq1.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2036-01-02 F2 · price: The stock option was granted pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer and has an exercise price of $23.82 per share. F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $6.40 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 14 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F9 · price: The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price. F8 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 13 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F9 · price: The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price. F8 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $15.36 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 12 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,100 shares Expires 2034-06-11 F7 · price: The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 11 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2034-06-11 F7 · price: The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $32.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 10 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2033-06-11 F6 · price: The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 9 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2033-06-11 F6 · price: The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $27.20 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 8 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2032-12-13 F5 · price: The reporting person agreed to cancellation of an option granted on December 14, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 7 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2032-12-13 F5 · price: The reporting person agreed to cancellation of an option granted on December 14, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $39.80 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 6 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2032-06-09 F4 · price: The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 5 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2032-06-09 F4 · price: The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $60.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 4 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2032-03-23 F3 · price: The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 3 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2032-03-23 F3 · price: The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,392 | Not disclosed Strike: $88.20 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 2 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,392 shares Expires 2030-12-28 F2 · price: The reporting person agreed to cancellation of an option granted on December 29, 2020, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:13 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,392 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321152 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,392 Underlying: Common Stock · 1,392 shares Expires 2030-12-28 F2 · price: The reporting person agreed to cancellation of an option granted on December 29, 2020, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 00:33 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 56,400 | $0.00 Strike: $9.60 | $0.00 |
DisclosureSEC source: 0001193125-25-259069 · ownership.xml · derivative · entry 5 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,400 shares Expires 2035-02-01 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 00:33 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 45,150 | $0.00 Strike: $9.98 | $0.00 |
DisclosureSEC source: 0001193125-25-259069 · ownership.xml · derivative · entry 4 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,150 shares Expires 2034-02-01 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 00:33 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 27,400 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001193125-25-259069 · ownership.xml · derivative · entry 3 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,400 shares Expires 2033-02-09 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 00:33 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001193125-25-259069 · ownership.xml · derivative · entry 2 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2032-05-16 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 00:33 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $18.68 | $0.00 |
DisclosureSEC source: 0001193125-25-259069 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2031-11-01 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 23, 2025 Filed Oct 28, 2025 01:16 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-25-251978 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 20:33 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 711 | $17.58 | $12,499.38 |
DisclosureSEC source: 0001104659-25-100109 · tm2528907-4_4seq1.xml · nonDerivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,862 F1 · shares: 711 shares of common stock were granted upon the close of business on October 15, 2025, as a consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q3-25. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:03 UTC | Precipio, Inc. PRPO · Entity 7207 | SaleCommon Stock | 6,152 | $20.06 | $123,409.12 |
DisclosureSEC source: 0001104659-25-089066 · tm2525773-1_4seq1.xml · nonDerivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,151 F1 · shares: The shares were initially granted to the Reporting Person on April 15, 2024 as consideration in lieu of cash of deferred compensation for service as a member of the issuer's board of directors from the first quarter of 2023 through the first quarter of 2024, as disclosed in the Form 4 filed with the Securities and Exchange Commission (the "SEC") on April 17, 2024. This grant was approved in advance by the issuer's board of directors in accordance with Rule 16b-3 under the Securities Exchange Act of 1934 and is exempt from Section 16(b). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 21:09 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 9,326 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001213900-25-050131 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,326 Underlying: Common Stock · 9,326 shares Expires 2035-05-29 F1 · shares: Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions. F1 · derivative.exercise_date: Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions. Read SEC document |
| May 27, 2025 Filed Jul 2, 2025 20:05 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 1,100 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0000950170-25-092938 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F1 · derivative.exercise_price: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F1 · shares: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F2 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. F1 · derivative.underlying_shares: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F1 · balance_after: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 21:01 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantCommon Stock | 2,232 | $5.60 | $12,499.20 |
DisclosureSEC source: 0001104659-25-036084 · tm2512512-2_4seq1.xml · nonDerivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,303 F1 · shares: 2,232 shares of common stock were granted upon the close of business on April 15, 2025, as a consideration in lieu of cash payment of compensation for service as a member of the Board of Directors for Q1-25. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:18 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 17,923 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001213900-25-021192 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,923 Underlying: Common Stock · 17,923 shares Expires 2035-03-03 F1 · shares: Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions. F1 · derivative.exercise_date: Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 23:02 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 127,500 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001213900-25-017518 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 127,500 shares Expires 2034-09-30 F1 · derivative.exercise_date: On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On February 24, 2025, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to the second installment, resulting in the vesting of 127,500 shares. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 12,767 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 6 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,767 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 5 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 1,947 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 4 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,947 Underlying: Common Stock · 1,947 shares Expires 2031-12-16 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,947 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 3 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,947 shares Expires 2031-12-16 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 5,431 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 2 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,431 Underlying: Common Stock · 5,431 shares Expires 2031-09-16 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,431 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0000950170-25-028268 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,431 shares Expires 2031-09-16 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:01 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantStock Option (Right to Buy) · Derivative | 56,400 | $0.00 Strike: $9.60 | $0.00 |
DisclosureSEC source: 0000950170-25-014438 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,400 Underlying: Common Stock · 56,400 shares Expires 2035-02-03 F1 · derivative.exercise_date: This option represents a right to purchase a total of 56,400 shares of the Issuer's Common Stock, which will vest in full on February 1, 2026, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 22:18 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001104659-25-004170 · tm253548-9_4seq1.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2035-01-14 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer. F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one-month anniversary of the date of the issuance. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 02:12 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | GrantStock Option (Right to Buy) · Derivative | 127,500 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001213900-24-105728 · ownership.xml · derivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,500 Underlying: Common Stock · 127,500 shares Expires 2034-09-30 F1 · derivative.exercise_date: On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On December 2, 2024, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 127,500 shares. Read SEC document |
| September 25, 2024 Filed Oct 3, 2024 01:53 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | Exercise / conversionSeries A Convertible Preferred Stock · Derivative | 50 | $1,000.00 | $50,000.00 |
DisclosureSEC source: 0001213900-24-084831 · ownership.xml · derivative · entry 3 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 965,997 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date. F1 · kind: On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date. F1 · derivative.exercise_date: On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date. F1 · derivative.expiration_date: On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date. Read SEC document |
| September 25, 2024 Filed Oct 3, 2024 01:53 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | Exercise / conversionCommon Stock | 965,997 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-084831 · ownership.xml · nonDerivative · entry 1 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By the Kathleen LaPorte Revocable Trust Disclosed balance after: 965,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date. F1 · price: On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date. F2 · ownership.nature: The reporting person is the trustee of the Kathleen LaPorte Revocable Trust (the "Trust") and has sole voting and disposition power with respect to the shares owned by the Trust. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 20 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2032-01-11 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $30.80 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 19 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2032-01-11 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 18 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2031-03-08 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $64.40 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 17 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2031-03-08 F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 31, 2024 Filed Sep 6, 2024 21:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0001104659-24-097789 · tm2423539-5_4seq1.xml · derivative · entry 16 LAPORTE KATHLEEN · CIK 0001196201 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2031-01-04 F3 · derivative.exercise_price: The exercise price of the option is $6.56 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service with the Issuer is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 30, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 31, 2024 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2017 Stock Option and Incentive Plan, as amended, (the "2017 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.